Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Allergy
Published in: Clinical and Translational Allergy 1/2018

Open Access 01-12-2018 | Research

Stevens–Johnson syndrome/toxic epidermal necrolysis and erythema multiforme drug-related hospitalisations in a national administrative database

Authors: Bernardo Sousa-Pinto, Luís Araújo, Alberto Freitas, Osvaldo Correia, Luís Delgado

Published in: Clinical and Translational Allergy | Issue 1/2018

Login to get access

Abstract

Background

Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and erythema multiforme (EM) are immunologically-mediated dermatological disorders commonly triggered by drug exposure and/or other external agents. We aimed to characterise SJS/TEN- and EM-drug-related hospitalisations in a nationwide administrative database, focusing on demographic and clinical characteristics, and in the most frequently implicated drug classes.

Methods

We analysed all drug-related hospitalisations with associated diagnosis of SJS/TEN or EM in Portuguese hospitals between 2009 and 2014. We compared gender, age, comorbidities, length of stay, and in-hospital mortality and estimated the number of episodes per million packages sold of drug classes. Predictors of in-hospital mortality were investigated in both conditions by logistic regression.

Results

There were 132 SJS/TEN-related and 122 EM-related hospitalisations. Incidence and in-hospital mortality of SJS/TEN episodes (24.2%) were consistent with previous studies. HIV co-infection was more common among SJS/TEN hospitalisations (9 vs. 2% with EM; P = 0.009). Liver disease, advanced age, and a TEN diagnosis, were significantly associated with higher risk of mortality in patients with SJS/TEN. The highest numbers of SJS/TEN and EM episodes per million drug packages sold were observed for antivirals (8.7 and 1.5, respectively), antineoplastic/immunosuppressive drugs (5.6 and 3.9, respectively) and hypouricaemic drugs (5.0 and 2.4, respectively).

Conclusions

SJS/TEN in-hospital mortality is high, and its risk factors include advanced age, liver disease, and TEN diagnosis. The drug classes most frequently associated with these conditions include antivirals, hypouricaemic drugs and antineoplastic/immunosuppressive drugs. Administrative databases seem useful in the study of SJS/TEN drug-related hospitalisations, yielding results consistent with previous studies and on a nationwide basis.
Appendix
Available only for authorised users
Literature
1.
Wheatley LM, Plaut M, Schwaninger JM, Banerji A, Castells M, Finkelman FD, et al. Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy. J Allergy Clin Immunol. 2015;136(262–71):e2.
2.
Pavlos R, Mallal S, Ostrov D, Pompeu Y, Phillips E. Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy. J Allergy Clin Immunol Pract. 2014;2:21–33.CrossRefPubMedPubMedCentral
3.
Swanson L, Colven RM. Approach to the patient with a suspected cutaneous adverse drug reaction. Med Clin N Am. 2015;99:1337–48.CrossRefPubMed
4.
Bouvresse S, Valeyrie-Allanore L, Ortonne N, Konstantinou MP, Kardaun SH, Bagot M, et al. Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist? Orphanet J Rare Dis. 2012;7:72.CrossRefPubMedPubMedCentral
5.
6.
Lin YF, Yang CH, Sindy H, Lin JY, Rosaline Hui CY, Tsai YC, et al. Severe cutaneous adverse reactions related to systemic antibiotics. Clin Infect Dis. 2014;58:1377–85.CrossRefPubMed
7.
Borchers AT, Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Stevens–Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev. 2008;7:598–605.CrossRefPubMed
8.
9.
Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol. 2003;4:561–72.CrossRefPubMed
10.
Roujeau JC. Stevens–Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol. 1997;24:726–9.CrossRefPubMed
11.
Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens–Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138:1019–24.CrossRefPubMed
12.
Marzano AV, Frezzolini A, Caproni M, Parodi A, Fanoni D, Quaglino P, et al. Immunohistochemical expression of apoptotic markers in drug-inducederythema multiforme, Stevens–Johnson syndrome and toxic epidermal necrolysis. Int J Immunopathol Pharmacol. 2007;20:557–66.CrossRefPubMed
13.
Watanabe R, Watanabe H, Sotozono C, Kokaze A, Iijima M. Critical factors differentiating erythema multiforme majus from Stevens–Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). Eur J Dermatol. 2011;21:889–94.PubMed
14.
Diphoorn J, Cazzaniga S, Gamba C, Schroeder J, Citterio A, Rivolta AL, et al. Incidence, causative factors and mortality rates of Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry. Pharmacoepidemiol Drug Saf. 2016;25:196–203.CrossRefPubMed
15.
Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600–7.CrossRefPubMed
16.
Chan EW, Liu KQ, Chui CS, Sing CW, Wong LY, Wong IC. Adverse drug reactions—examples of detection of rare events using databases. Br J Clin Pharmacol. 2015;80:855–61.CrossRefPubMedPubMedCentral
17.
Mateus C. Portugal. Results of 25 years of experience with DRGs. In: Busse R, World Health Organization, Regional Office for Europe, EuroDRG (Project), , editors. Diagnosis-related groups in Europe: moving towards transparency, efficiency and quality in hospitals. Berkshire: McGraw-Hill Open University Press; 2011.
18.
Davis RL, Gallagher MA, Asgari MM, Eide MJ, Margolis DJ, Macy E, et al. Identification of Stevens–Johnson syndrome and toxic epidermal necrolysis in electronic health record databases. Pharmacoepidemiol Drug Saf. 2015;24:684–92.CrossRefPubMed
19.
20.
Sousa-Pinto B, Correia C, Gomes L, Gil-Mata S, Araújo L, Correia O, et al. HLA and delayed drug-induced hypersensitivity. Int Arch Allergy Immunol. 2016;170:163–79.CrossRefPubMed
21.
Ramasamy SN, Korb-Wells CS, Kannangara DR, Smith MW, Wang N, Roberts DM, et al. Allopurinol hypersensitivity: a systematic review of all published cases, 1950–2012. Drug Saf. 2013;36:953–80.CrossRefPubMed
22.
Rzany B, Mockenhaupt M, Stocker U, Hamouda O, Schopf E. Incidence of Stevens–Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. Arch Dermatol. 1993;129:1059.CrossRefPubMed
23.
Gao W, Tiwary A, McGann A, Rajmane R. Chronic infection with hepatitis C as a risk factor for toxic epidermal necrolysis in a cirrhotic patient with streptococcus pneumoniae bacteremia. Chest. 2011;140(4_MeetingAbstracts):124A.CrossRef
24.
25.
26.
27.
28.
29.
Samim F, Auluck A, Zed C, Williams PM. Erythema multiforme: a review of epidemiology, pathogenesis, clinical features, and treatment. Dent Clin N Am. 2013;57:583–96.CrossRefPubMed
30.
Roujeau JC. Re-evaluation of ‘drug-induced’ erythema multiforme in medical literature. Br J Dermatol. 2016;175:650–1.CrossRefPubMed
31.
Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol. 2003;83:1–9.CrossRefPubMed
32.
Yang C, Mosam A, Mankahla A, Dlova N, Saavedra A. HIV infection predisposes skin to toxic epidermal necrolysis via depletion of skin-directed CD4(+) T cells. J Am Acad Dermatol. 2014;70:1096–102.CrossRefPubMed
33.
Correia O, Delgado L, Santos C, Miranda AM. HIV-1 in blister fluid of a patient with toxic epidermal necrolysis and AIDS. Lancet. 1994;344:1432–3.CrossRefPubMed
34.
Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens–Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58:33–40.CrossRefPubMed
35.
Finkelstein Y, Macdonald EM, Li P, Hutson JR, Juurlink DN. Recurrence and mortality following severe cutaneous adverse reactions. JAMA. 2014;311:2231–2.CrossRefPubMed
36.
Sekula P, Liss Y, Davidovici B, Dunant A, Roujeau JC, Kardaun S, et al. Evaluation of SCORTEN on a cohort of patients with Stevens–Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res. 2011;32:237–45.CrossRefPubMed
37.
Heng YK, Lim YL. Cutaneous adverse drug reactions in the elderly. Curr Opin Allergy Clin Immunol. 2015;15:300–7.CrossRefPubMed
38.
Devarbhavi H, Raj S, Aradya VH, Rangegowda VT, Veeranna GP, Singh R, et al. Drug-induced liver injury Associated with Stevens-Johnson syndrome/toxic epidermal necrolysis: patient characteristics, causes and outcome in 36 Cases. Hepatology. 2016;63:993–9.CrossRefPubMed
39.
Payne AS, James WD, Weiss RB. Dermatologic toxicity of chemotherapeutic agents. Semin Oncol. 2006;33:86–97.CrossRefPubMed
40.
Sanborn RE, Sauer DA. Cutaneous reactions to chemotherapy: commonly seen, less described, little understood. Dermatol Clin. 2008;26:103–19.CrossRefPubMed
41.
Vern-Gross TZ, Kowal-Vern A. Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis syndrome in patients undergoing radiation therapy: a literature review. Am J Clin Oncol. 2014;37:506–13.CrossRefPubMed
42.
Miguel A, Bernardo M, Freitas A, Lopes F, Azevedo L, Pereira AC. Detection of adverse drug reactions using hospital databases—a nationwide study in Portugal. Pharmacoepidemiol Drug Saf. 2013;22:907–13.CrossRefPubMed
43.
44.
Hsu DY, Brieva J, Silverberg NB, Paller AS, Silverberg JI. Pediatric Stevens–Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol. 2017;76(811–7):e4.
45.
Schneider G, Kachroo S, Jones N, Crean S, Rotella P, Avetisyan R, et al. A systematic review of validated methods for identifying erythema multiforme major/minor/not otherwise specified, Stevens–Johnson Syndrome, or toxic epidermal necrolysis using administrative and claims data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):236–9.CrossRefPubMed
46.
Saff RR, Camargo CA, Jr, Clark S, Rudders SA, Long AA, Banerji A. Utility of ICD-9-CM codes for identification of allergic drug reactions. J Allergy Clin Immunol Pract. 2016;4:114–9.CrossRefPubMed
47.
Nomura H, Takahashi H, Suzuki S, Kurihara Y, Chubachi S, Kawada I, et al. Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy. J Dermatol. 2017;44:818–21.CrossRefPubMed
48.
Laurinaviciene R, Sandholdt LH, Bygum A. Drug-induced cutaneous lupus erythematosus: 88 new cases. Eur J Dermatol. 2017;27:28–33.PubMed
49.
50.
Tanno LK, Calderon MA, Li J, Casale T, Demoly P, Joint Allergy Academies. Updating allergy and/or hypersensitivity diagnostic procedures in the WHO ICD-11 revision. J Allergy Clin Immunol Pract. 2016;4:650–7.CrossRefPubMed
51.
Metadata
Title
Stevens–Johnson syndrome/toxic epidermal necrolysis and erythema multiforme drug-related hospitalisations in a national administrative database
Authors
Bernardo Sousa-Pinto
Luís Araújo
Alberto Freitas
Osvaldo Correia
Luís Delgado
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Clinical and Translational Allergy / Issue 1/2018
Electronic ISSN: 2045-7022
DOI
https://doi.org/10.1186/s13601-017-0188-1

Other articles of this Issue 1/2018

Clinical and Translational Allergy 1/2018 Go to the issue

Research

Development and validation of a standardized double-blind, placebo-controlled food challenge matrix for raw hazelnuts

Research

Tonsillar cytokine expression between patients with tonsillar hypertrophy and recurrent tonsillitis

Study protocol

Early aggressive intervention for infantile atopic dermatitis to prevent development of food allergy: a multicenter, investigator-blinded, randomized, parallel group controlled trial (PACI Study)—protocol for a randomized controlled trial

Letter to the Editor

Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey

Letter to the Editor

Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab

Research

Interleukin-25 and eosinophils progenitor cell mobilization in allergic asthma